Possibilities of PET/CT with 18F-PSMA-1007 in the Diagnosis of Triple Negative Breast Cancer: a Case Study
A. V. Parnas,
A. A. Odzharova,
A. I. Pronin,
V. S. Ilyakov,
N. A. Meshcheryakova,
Z. Kh. Kamolova,
D. I. Nevzorov https://doi.org/10.37174/2587-7593-2021-4-4-88-92
Abstract
Breast cancer (BC) is one of the most common cancers and the leading cause of cancer death in women. Triple negative breast cancer (TNBC) is a specific subtype of breast cancer that does not express estrogen receptors (ER), progesterone receptors (RP) or human epidermal growth factor receptor-2 (HER-2), has certain clinical features, a tendency to relapses and poor prognosis. Various studies demonstrate that prostate-specific antigen (PSA) is not strictly specific for prostate cancer, and can be produced by other tumor pathologies. In routine practice, PET/CT for TNBC is performed with 18F-FDG. However PET/CT with 18F-PSMA-1007 can be used as the method of choice with high theranostic potential. Here is a clinical case of a patient with TNBC who underwent PET/CT with 18F-FDG and 18F-PSMA-1007.
About the Authors
A. V. Parnas
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
A. A. Odzharova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
A. I. Pronin
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
V. S. Ilyakov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
N. A. Meshcheryakova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Z. Kh. Kamolova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
D. I. Nevzorov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
References
1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-49. DOI: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938-48. DOI: 10.1056/NEJMra1001389. PMID: 21067385.
3. Morgenroth A, Tinkir E, Vogg ATJ, et al. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer. Breast Cancer Res. 2019;21:116. DOI: 10.1186/s13058-019-1205-1.
4. Uría JA, Velasco G, Santamaría I, et al. Prostate-specific membrane antigen in breast carcinoma. Lancet. 1997;349(9065):1601. DOI: 10.1016/s0140-6736(05)61629-7.
5. Miladinova D. Molecular Imaging in Breast Cancer. Nucl Med Mol Imaging. 2019 Oct;53(5):313-9. DOI: 10.1007/s13139-019-00614-w. Epub 2019 Oct 16. PMID: 31723360; PMCID: PMC6821902.
6. Kasoha M, Unger C, Solomayer EF, et al. Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases. Clin Exp Metastasis. 2017 Dec;34(8):479-90. DOI: 10.1007/s10585-018-9878-x. Epub 2018 Feb 10. PMID: 29426963.
7. Bertagna F, Albano D, Cerudelli E, et al. Radiolabelled PSMA PET/CT in breast cancer. A systematic review. Nucl Med Rev Cent East Eur. 2020;23(1):32-5. DOI: 10.5603/NMR.2020.0004. PMID: 32779172.
8. Tolkach Y, Gevensleben H, Bundschuh R, et al. Prostatespecific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Research and Treatment. 2018;169(3):447-55. DOI: 10.1007/s10549-018-4717-y.
Review
For citations:
Parnas A.V., Odzharova A.A., Pronin A.I., Ilyakov V.S., Meshcheryakova N.A., Kamolova Z.Kh., Nevzorov D.I. Possibilities of PET/CT with 18F-PSMA-1007 in the Diagnosis of Triple Negative Breast Cancer: a Case Study. Journal of oncology: diagnostic radiology and radiotherapy. 2021;4(4):88-92. (In Russ.) https://doi.org/10.37174/2587-7593-2021-4-4-88-92
Views:
761
Email this article 